A phase III trial for daraxonrasib, a RAS-targeting treatment, has shown promise in the treatment of pancreatic cancer. The trial's results indicate that daraxonrasib may extend survival in patients with previously treated metastatic pancreatic adenocarcinoma. The treatment is seen as a potential advancement in pancreatic cancer therapy, with further developments and potential approvals anticipated.